Effects of downhill walking on patients with idiopathic pulmonary fibrosis
Official title: Effects of Downhill Walking in Pulmonary Rehabilitation for Patients With Idiopathic Pulmonary Fibrosis
Run by Saglik Bilimleri Universitesi · NCT06756230 · Data updated 2026-11-12
This study is testing if downhill walking can help people with idiopathic pulmonary fibrosis feel better and improve their exercise ability compared to regular walking programs.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 34 (estimated) |
| Sponsor | Saglik Bilimleri Universitesi Academic / other |
| Locations | 1 site (Istanbul, Üsküdar) |
| Status | Recruiting |
| Started | May 13, 2025 |
| Main results expected | February 28, 2027 |
| Study ends | February 28, 2027 |
| Registry record updated | May 16, 2025 |
| Trial ID | NCT06756230 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 to 75 with a confirmed diagnosis of idiopathic pulmonary fibrosis who can walk on a treadmill.
✕Probably not a fit
Patients with significant cardiovascular disease, orthopedic limitations, or those unable to comply with the rehabilitation protocol may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the impact of downhill walking, a form of eccentric exercise training, on exercise capacity, quality of life, and blood lactate levels in individuals diagnosed with idiopathic pulmonary fibrosis (IPF). Participants will be randomized into two groups: one receiving downhill walking pulmonary rehabilitation and the other undergoing standard pulmonary rehabilitation. The exercise sessions will occur twice a week for eight weeks, with evaluations conducted before and after the program. The aim is to determine if downhill walking offers benefits over traditional walking protocols.
Why it matters
Potential benefit: If successful, this approach could enhance exercise capacity and quality of life for patients with IPF.
How similar studies have gone: While eccentric exercise training is a relatively novel approach in this context, similar studies have shown promising results in other populations, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Having a diagnosis of IPF according to the clinical diagnostic criteria of the American Thoracic Society and/or the European Respiratory Society (ATS-ERS). * Being between the ages of 18 and 75. * Being able to walk on a treadmill. * Having the ability to cooperate. * No change in current medication in the last month. * Not participating in a structured activity program for at least six months. * Accepting the purpose and method of this study voluntarily and give informed consent for the study. Exclusion Criteria: * Presence of physical or mental impairment that prevents informed consent or compliance with the protocol. * Inability to attend more than 20% of pulmonary rehabilitation sessions. * Presence of major cardiovascular disease (coronary artery disease, uncontrolled hypertension, arrhythmias, or heart failure). * Presence of existing orthopedic and neuromuscular exercise limitations. * Acute exacerbation
Where it's running
-
Saglik Bilimleri Universitesi
Istanbul, Üsküdar, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Esra PEHLIVAN, Associate Professor
- Email: fztesrakambur@yahoo.com
- Phone: 02164189616
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Nerandomilast in IPF and Progressive Fibrosis: Real-World Data
This study tests whether nerandomilast helps slow lung function decline in adults with IPF or progressive fibrotic lung disease in routine clinical care.
-
Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs
This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.
-
Finger vs. Earlobe Pulse Oximetry During a 6-Minute Walk Test in ILD
This study tests whether finger or earlobe pulse oximetry gives the same oxygen saturation readings during a 6-minute walk in people with interstitial lung disease.
-
Biomarker clues for COPD, IPF, and lung cancer
This study tests whether inflammation, immune, genetic, and epigenetic markers at enrollment can explain how COPD, IPF, or lung cancer present and behave, in order to see if these markers can predict outcomes over a year.
-
Inhaled nintedanib powder for IPF in adults
This study tests whether an inhaled form of nintedanib can safely help adults with idiopathic pulmonary fibrosis.
-
AZD8965 in IPF: see if three doses help IPF patients
This Phase IIb study tests three doses of AZD8965 against placebo in people with idiopathic pulmonary fibrosis, including those who are and aren’t on antifibrotic therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.